Literature DB >> 20979170

Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1.

Marta Campagna1, Enrico Opocher, Elisabetta Viscardi, Milena Calderone, Savina Maria Severino, Iveta Cermakova, Giorgio Perilongo.   

Abstract

BACKGROUND: Little is known about the visual outcome of children affected by an optic pathway glioma (OPG). PROCEDURES: We evaluated the long-term visual outcome of 32 consecutive children affected by OPG without neurofibromatosis type-1 referred to the Pediatric Department of Padua University and managed according to standardized strategies.
RESULTS: Eight children received chemotherapy, 10 radiotherapy, 7 both chemotherapy and radiotherapy, whereas 7 were untreated. At presentation, visual acuity (VA) was normal in 22 children (13 unilaterally and 9 bilaterally), and reduced in 10. At follow-up, VA had improved in 6 patients; it was stable in 8 and worse in 18. Visual field, assessed in 29 children, was normal in 9 and reduced in 20. The number of children with some grade of visual impairment increased from 7 to 10 during follow-up. Of the 17 children in whom the tumor became significantly smaller, VA improved in 6, was stable in 3, and worse in 8. Of the 6 children with improved VA, 5 received radiotherapy, and their papilla was normal or mildly pale. After a median follow-up of 6 years, 26 patients are alive with stable disease.
CONCLUSIONS: The visual prognosis of children with OPG is unsatisfactory. Older children treated with radiotherapy seem to have a better visual outcome than younger children. Severe optic pallor at diagnosis or during follow-up may be indicative of a negative prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 20979170     DOI: 10.1002/pbc.22748

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  26 in total

1.  Neurofibromatosis 1-associated optic pathway gliomas.

Authors:  Ben Shofty; Liat Ben Sira; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-11       Impact factor: 1.475

2.  Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.

Authors:  Peter Matthew Kennedy de Blank; Jeffrey Ira Berman; Grant T Liu; Timothy Paul Leslie Roberts; Michael Jay Fisher
Journal:  Neuro Oncol       Date:  2013-05-07       Impact factor: 12.300

Review 3.  Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review.

Authors:  Fumiyuki Yamasaki; Motoki Takano; Ushio Yonezawa; Akira Taguchi; Manish Kolakshyapati; Hideaki Okumichi; Yoshiaki Kiuchi; Kaoru Kurisu
Journal:  Childs Nerv Syst       Date:  2019-11-07       Impact factor: 1.475

4.  Impact of vision loss among survivors of childhood central nervous system astroglial tumors.

Authors:  Peter M K de Blank; Michael J Fisher; Lu Lu; Wendy M Leisenring; Kirsten K Ness; Charles A Sklar; Marilyn Stovall; Chris Vukadinovich; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  Cancer       Date:  2016-01-11       Impact factor: 6.860

5.  Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.

Authors:  Michael J Fisher; Michael Loguidice; David H Gutmann; Robert Listernick; Rosalie E Ferner; Nicole J Ullrich; Roger J Packer; Uri Tabori; Robert O Hoffman; Simone L Ardern-Holmes; Trent R Hummel; Darren R Hargrave; Eric Bouffet; Joel Charrow; Larissa T Bilaniuk; Laura J Balcer; Grant T Liu
Journal:  Neuro Oncol       Date:  2012-04-03       Impact factor: 12.300

Review 6.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

7.  Handheld optical coherence tomography during sedation in young children with optic pathway gliomas.

Authors:  Robert A Avery; Eugene I Hwang; Hiroshi Ishikawa; Maria T Acosta; Kelly A Hutcheson; Domiciano Santos; Dina J Zand; Lindsay B Kilburn; Kenneth N Rosenbaum; Brian R Rood; Joel S Schuman; Roger J Packer
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

Review 8.  Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research.

Authors:  Robert A Avery; Rosalie E Ferner; Robert Listernick; Michael J Fisher; David H Gutmann; Grant T Liu
Journal:  J Neurooncol       Date:  2012-07-28       Impact factor: 4.130

9.  Vision specific quality of life in children with optic pathway gliomas.

Authors:  Robert A Avery; Kristina K Hardy
Journal:  J Neurooncol       Date:  2013-11-07       Impact factor: 4.130

10.  Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.

Authors:  Joann L Ater; Caihong Xia; Claire M Mazewski; Timothy N Booth; David R Freyer; Roger J Packer; Richard Sposto; Gilbert Vezina; Ian F Pollack
Journal:  Cancer       Date:  2016-04-08       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.